All rights reserved. No reuse allowed without permission.

Stratification of hypertensive COVID-19 patients by 1 quantitative NMR spectroscopy of serum metabolites, 2 lipoproteins and inflammation markers 3

Jasmin Kazenwadel¹, Georgy Berezhnoy¹, Claire Cannet², Hartmut Schäfer², Tobias 5 Geisler³, Anne-Katrin Rohlfing³, Meinrad Gawaz³, Uta Merle⁴⁺, Christoph Trautwein^{1*+} 6

¹ Werner Siemens Imaging Center, Department for Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Germany

² Bruker BioSpin GmbH, Applied Industrial and Clinical Division, Ettlingen, Germany

³ Department of Internal Medicine III, Cardiology and Angiology, University Hospital Tübingen, Tübingen, Germany

⁴ Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany

* Author to whom correspondence should be addressed: Christoph.Trautwein@med.uni-tuebingen.de

⁺ These authors contributed equally to this work.

20 Abstract

4

7

8

9 10

11 12

13 14

15 16

17 18

19

21 Background: The exact pathophysiology of humans suffering from the multifaceted SARS-CoV-2

22 infection is not yet conclusively understood and risk stratification is needed. Novel diagnostic

23 approaches like the nuclear magnetic resonance spectroscopy (NMR) based quantification of

24 metabolites, lipoproteins, and inflammation markers has helped to identify typical alterations in the

25 blood serum of COVID-19 patients. However, important confounders such as age, sex, and

26 comorbidities, which strongly influence the metabolome, were often not considered. Therefore, the

27 aim of this NMR study was to consider gender, as well as arterial hypertension (AHT) which affects

28 more than 1.2 billion people worldwide, when investigating COVID-19-positive serum samples in a

29 large age-matched cohort. As AHT is a risk factor for severe COVID-19 disease, this study focuses on 30

comparing metabolomic characteristics of COVID-19 patients with and without AHT.

31 Methods and Findings: NMR serum data from 329 COVID-19 patients were compared with 305

32 individuals from a healthy age and sex-matched control cohort. 134 of the 329 COVID-19 patients 33 were affected by AHT. These were analyzed together with NMR data from 58 hypertensives without

- 34 COVID-19. In addition to metabolite, lipoprotein, and glycoprotein data from NMR, common
- 35 laboratory parameters were considered. Statistical comparison of the COVID-19 cohort with the
- 36 control cohort reproduced results of previous studies. However, several differences emerged when
- 37 AHT was considered. Especially, the previously described triglyceride-rich lipoprotein profile was no 38 longer observed in COVID-19 patients, nor was an increase in ketone bodies. Typical metabolic
- 39 changes that were apparent in COVID-19 patients in both sexes and with AHT were an increase in C-
- 40 reactive protein (CRP) and the ratio of total glycoprotein (Glyc) to supramolecular phospholipids

41 composite (SPC) which is an inflammatory NMR parameter. Further alterations were a decrease in

- 42 glutamine, leucine, isoleucine, and lysine, citric acid, HDL-4 particles, and total cholesterol. Typical
- 43 metabolic cardiovascular risk markers could be detected in hypertensive COVID-19 patients, as well

44 as higher inflammatory NMR parameters than in normotensive COVID-19 patients.

45 **Conclusion:** We could show that a more precise picture of COVID-19 blood serum parameters

46

emerge when AHT is considered which accordingly should be included in future studies and would NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. help for a refined patient stratification. 47

Abbreviations 48

Name	Extended name
ACEI	Angiotensin- converting- enzyme inhibitor
AHT	Arterial hypertension
AT1RB	Angiotensin-1 receptor blockers
AUC	Area under the curve
BB	Beta blockers
BCAA	Branched chained amino acids (leucine, isoleucine, valine)
ВР	Blood pressure
BUN	Blood urea nitrogen
ССВ	Calcium channel blockers
Creatinine.lab	Creatinine (laboratory report)
CRP	C- reactive protein
FC	Fold change
FDR	False Discovery rate
GFR	Glomerular filtration rate
GGT	Gamma-glutamyl transferase
Glyc	Glycoproteins
GOT	Glutamate- oxalacetate- transferase
HC	Healthy cohort
Leuk	Leucozytes
LDH	Lactat dehydrogenase
NMR	Nuclear magnetic resonance
SPC	Supramolecular phospholipid composite
T2DM	Diabetes mellitus Type 2
TMAO	Trimethylamine-N-oxide
PACS	Post-acute-covid- syndrom
PCA	Principal component analysis
RAASI	Renin-angiotensin-aldosterone- system inhibitors

49

Introduction 50

51	To date, the SARS- CoV- 2 virus, which emerged in Wuhan, China in December 2019, has infected
52	more than 612 million people worldwide and caused 6.5 million deaths from December 2019 to
53	September 2022 (WHO). COVID-19 infection can manifest in a wide range of symptoms with varying
54	disease severity. Patients often report mild flu-like symptoms or asymptomatic courses. In some
55	cases, however, intensive medical treatment may be necessary or the infection may be fatal.
56	Furthermore, various complications can arise during the course of the disease, which can affect
57	multiple organ systems. These include sepsis, acute respiratory distress syndrome (ARDS) (1), and
58	thromboembolic events such as pulmonary emboli (2) or myocardial infarction (3). Since the
59	beginning of the pandemic, there have been extensive efforts to identify causes and risk factors for

severe COVID-19 progression. Several studies have demonstrated that higher age, male gender, and
pre-existing conditions such as arterial hypertension (AHT) or diabetes mellitus (DM) may be risk
factors for a more severe COVID-19 course and hospitalization. (4, 5).

63 One way to better understand COVID-19 disease is the use of novel quantitative omics approaches 64 such as nuclear magnetic resonance (NMR) spectroscopy. With this method, a variety of metabolites and lipoproteins can be rapidly quantified in serum from numerous samples. Thus, a metabolic 65 66 fingerprint of a disease can be identified, which can help to better understand pathogenesis, 67 therapeutic effects, and to identify biomarkers for a more comprehensive diagnosis (6, 7). For COVID-19, several studies have investigated the metabolome and lipoproteome of patient sera both in the 68 69 acute stage of infection and in the so-called post-acute COVID syndrome. In these studies, it is 70 apparent that there are diverse changes in metabolites during COVID-19 infection. These include a 71 decrease in various amino acids such as histidine, glutamine, lysine, methionine and tyrosine, 72 whereas the amino acid phenylalanine showed increased levels in the studies in COVID-19 patients, 73 and furthermore a general increase in ketone bodies was observed (8-10). COVID- 19 patients also 74 showed signs of dyslipidemia with increased levels of very low density lipoprotein (VLDL) particles, 75 triglycerides in total plasma and in lipoprotein subgroups, and a decrease in high density (HDL) and 76 low density lipoprotein (LDL) major and subgroups, which include phospholipids, cholesterol, and 77 apolipoproteins A1 and A2 (8, 11-14). Also, the ABA1 ratio (apolipoprotein B100 divided by 78 apolipoprotein A1) which is considered a cardiovascular risk marker (15), was increased in several 79 COVID-19 cohorts (12, 13). In addition to the quantification of metabolites and lipoproteins in COVID-80 19 patients, it was possible to make statements about the outcome of patients (9). Accordingly, in hospitalized patients with positive outcome, i.e., in Baranovicova et al. survivors without respiratory 81 82 deterioration or mechanical ventilation, normalization of energy metabolism occurred more rapidly, 83 as well as an increase in glutamine, than in patients with negative outcome (deterioration of 84 respiratory situation with need for respiratory support or death). Furthermore, NMR technology has 85 identified markers that may be indicative of a severe COVID-19 progression (10, 16-18). As such,

86 above all, increased ketone bodies (16), phenylalanine (16, 17) and pronounced dyslipidemia with 87 increased ABA1 ratio, decreased HDL cholesterol (16) and decreased apolipoprotein A1 (18) had 88 been mentioned. These markers could help to predict response to therapy (16, 19). This was 89 investigated in these two studies with the IL-6 inhibitor tocilizumab, where under and after therapy, 90 respectively, an approximation of the metabolic/lipoproteomic parameters of severe COVID-19 cases 91 to the levels of milder cases was observed. Regarding the post-acute COVID syndrome (PACS), which 92 can also present with a wide range of symptoms (20) and precise disease mechanisms are still 93 unclear, NMR spectroscopy has shown that PACS is associated with delayed metabolic 94 phenoreversion and that the metabolome and lipoproteome still differ from healthy controls one to 95 three months after acute infection (21, 22). 96 In addition to the metabolites and lipoprotein fractions discussed so far, N- acetylated- glycoproteins 97 can be quantified by NMR as well. These include the GlycA signal, which is caused by various acute 98 phase proteins such as haptoglobin, α 1-acid glycoprotein, α 1- antitrypsin, α 1- antichymotrypsin and 99 transferrin. (23). GlycA is combined with GlycB, which represents N-acetylneuraminic acid (24), to 100 form the Glyc signal and thus maps inflammatory processes (25). Furthermore, Glyc is associated 101 with increased cardiovascular risk (26, 27). Elevated Glyc levels were also found in COVID-19 (14). 102 Another recent NMR parameter is the supramolecular phospholipids composite peak (SPC), which 103 correlates mainly with apolipoproteins and HDL subfractions and is thus decreased in COVID-19 104 sufferers (28).

As mentioned earlier, cardiovascular disease and diabetes mellitus are among the risk factors for
more severe COVID-19 progression (4). These diseases also exhibit diverse alterations in the
metabolome and lipoproteome. E.g. in patients with essential arterial hypertension, altered amino
acid metabolism has been found, with decreased alanine and methionine levels, and increased
arginine levels (29). Lactate and pyruvate were also elevated in hypertensives in one study (30).
Furthermore, hypertensive patients show increased levels of cholesterol and triglycerides, as well as
increased VLDL and LDL particles with reduced HDL and thus also an increased ABA1 ratio. (31).

Elevated serum phenylalanine levels and monounsaturated fatty acids were markers of increased
cardiovascular risk in another study (32). Changes in amino acid metabolism are also found in type 2
diabetes mellitus (T2DM), indicating impaired energy metabolism (33). In particular, impaired
branched chained amino acid metabolism was conspicuous in this study in diabetic patients with late
complications.

117 Aim of this study

- 118 Cardiovascular disease has both a high prevalence and an impact on metabolites and lipoproteins
- 119 concentrations in blood serum. Previous studies have taken this mostly not into account when
- 120 investigating the metabolic phenotype of COVID-19 acute disease. Therefore, in this study, NMR data
- and laboratory parameters from 58 uninfected hypertensive individuals were compared with 216
- 122 samples of COVID-19 affected individuals also suffering from hypertension, and the influence of AHT
- 123 on the previous findings on metabolic characteristics of COVID-19 was investigated. In our analyses,
- 124 we demonstrated that the stratification for AHT resulted in a well-refined picture of the NMR based
- metabolic phenotype of COVID-19. Furthermore, 509 samples of COVID-19 affected individuals with
- 126 and without hypertension were compared to derive conclusions about risks that could drive a severe
- 127 disease progression. It was found that hypertensive patients with COVID-19 showed metabolic
- 128 cardiovascular risk factors and increased inflammatory parameters.
- 129 Material and Methods

130 Patient cohort & sample collection

The COVID-19 study population (September 7th 2020 to May 17th 2021) consisted of patients
monitored with the "Coronataxi digital early warning" (CDEW) system deployed in Rhein-Neckar
County and Heidelberg, Germany - an outpatient care system consisting of remote digital monitoring
via a mobile application (with symptom questionnaire and daily pulse oximetry), a medical doctor
dashboard and medical care delivery to COVID-19 patients in home quarantine when indicated (34).

Visits in home quarantine were initiated when, based on the data obtained from the initial survey
and all available self-reported data (e.g. self-reported dyspnea), a medical doctor at the university
hospital decided whether a visit in home quarantine by a nurse was indicated and scheduled the visit
for the following day.

This was a prospective non-interventional study conducted at the University of Heidelberg. Patients were eligible if they for were diagnosed with SARS-CoV-2 infection and if they had consented to study participation. Written informed consent according to the Declaration of Helsinki was obtained for all patients and the local Ethics committee had approved data collection and analysis (reference number: S-324/2020).

145 Blood sample collection took place during home visits by nurses (the cohort and study therefore was 146 called "Coronataxi"), which were carried out on medical indication e.g. worsening of symptoms. 147 Therefore, the blood samples were not taken a fastened state and there are various numbers of 148 samples per study participant from zero to three. Also, the time intervals between blood collections 149 varied. From a total of 459 participants in the Coronataxi study, a total of 543 samples from 348 150 COVID-19 patients was received and investigated by NMR. In interest to get the full statistical power, 151 we took chance of using the NMR data of all samples, even there were several specimens of the 152 same patient. This is a common approach in metabolomics studies. Blood was collected in Li-heparin 153 or EDTA- containing tubes. The specimens were then transported in isolated polystyrene boxes and 154 centrifuged for serum preparation in the afternoon in the laboratory of Heidelberg University 155 Hospital, Germany. A frozen aliquot of the supernatant of these samples was transported to 156 Tübingen, Germany on dry ice and stored at -80 degrees Celsius until further processing and NMR 157 analysis

Besides common laboratory parameters (e.g. creatinine, C- reactive protein, white blood cell count
and other) extensive metadata were provided by the University hospital Heidelberg, Heidelberg,

160 Germany e.g. information about anthropometrics, age, medication and pre- existing diseases. The

161 metadata is listed in Table 1 and in the supplementary data S1.

162 The cohort of the 58 arterial hypertension patients were provided by the interdisciplinary 163 biomaterial- and databank of Würzburg University Hospital, Germany and were age and sex matched 164 with the Heidelberger COVID-19 cohort. They were stored at -80 degrees Celsius, until further 165 processing. The metadata belonging to the serum samples was provided by the institute for clinical 166 epidemiology and biometry Würzburg, Germany. Study enrollment of participants and collection of 167 samples took place between July 2019 and February 2022. The pre-disease AHT was recorded as part 168 of the patient's medical history. Further metadata contained information about age, sex, medication, 169 diabetes mellitus as co- disease and common laboratory parameters, including renal values 170 (creatinine, blood urea nitrogen, GFR), small blood count, inflammatory values (e.g., CRP), and 171 isolated liver values. The relevant metadata for this work is listed in Table 2. An overview about the 172 antihypertensive treatment is given in Table 3. For the patient recruitment, which took place in 173 Tübingen, Germany, there is an ethics vote with the number 141/2018BO2, dated May 4, 2022. Since the data were kept in Würzburg, Germany, there is a second ethics vote with the number 52/18. 174 175 For improved statistical analysis, further NMR data (metabolites and lipoproteins) of an age and sex 176 matched healthy control cohort (HC) of 305 subjects were provided by Bruker BioSpin GmbH 177 (Ettlingen, Germany). These data did not contain any clinical laboratory parameters.

178 Sample preparation and NMR measurement

179 The raw NMR spectra were acquired using Bruker's body fluids NMR methods package

180 [https://www.bruker.com/de/products-and-solutions/mr/nmr-clinical-research-solutions/b-i-

181 methods.html]. The sample preparation was performed following standard operating procedures

182 (SOPs) to perform reproducible results. Briefly, blood serum samples were thawed to room

temperature. Then 400 μl of commercially available plasma/serum buffer (Bruker BioSpin GmbH,

184 Ettlingen, Germany) were pipetted into a 1,5 ml sterile Eppendorf tube. Next, an aliquot of 400 μl

185 serum was added to the buffer. After gently shaken, an aliquot of 600 μ l of the mixture was 186 transferred into a 5 mm Bruker SampleJet NMR tube. Since only 350 µl was available for the cohort 187 with the 58 hypertensive patients, 320 µl serum aliquot was added to 320 µl Bruker Plasma buffer 188 (resulting in the same 1:1 mixing ratio) and an aliquot of 600μ l was used for measurement. 189 NMR spectroscopy was performed with a Bruker BioSpin IVDr Avance III HD 600 MHz system. It uses 190 a temperature-controlled autosampler SampleJet[™] for gentle handling during the measurements. 1D 191 ¹H-NMR spectra of the NOESY experiment (Nuclear Overhauser Spectroscopy) at a temperature of 192 310 K were acquired. NOESYs were analyzed using Bruker's software TopSpin (Version 3.6.2) and 193 automatically processed. For the highest standardization and amount of reproducibility the following 194 NMR-based commercial IVDr SOPs (standard operation procedures) were used to collect the data 195 sets for quality control, metabolites, lipoproteins, and inflammatory markers: B.I.BioBankQC[™] in 196 Plasma/Serum (Quality Control for Biobank Blood Samples), B.I.Quant-PS[™] (quantification of up to 41 metabolites in serum in mmol/L), B.I.LISA[™] (Lipoprotein analysis for 112 lipoprotein variables in 197 198 serum), and B.I. PACS™ (quantification of two metabolites, nine lipoprotein variables, SPC and 199 inflammatory markers e.g., GlycA/GlycB and Glyc/SPC ratio which provide information related to 200 various complications in the context of post-acute COVID-19 syndrome).

201 Lipoprotein concentrations provided by the B.I. LISA[™] package are divided in various subfractions 202 broken down by triglycerides (TG), cholesterol (CH), apolipoproteins A1/ -A2, apolipoprotein B100 203 bearing particles (AB), and total particle numbers (PN). These subfractions exist in the individual 204 lipoprotein classes, very-low-density (VLDL), intermediate density (IDL), low-density (LDL), and high-205 density lipoproteins (HDL). Additionally, the above mentioned subfractions (TG, CH, A1, A2, AB, PN) 206 are also available in total plasma concentrations (TP). Phospholipid (PL) and free cholesterol (FC) 207 fractions are also provided within the lipoprotein panel. Furthermore, the lipoproteins are 208 subdivided according to size and thus increasing density. VLDL can be subdivided by NMR into five 209 sizes, LDL into six, and HDL into four whereas an increasing number is associated with smaller size or 210 higher density.

Glycoproteins (Glyc A, Glyc B, Glyc) and the supramolecular phospholipid composite (SPC) data from
the B.I. PACS[™] module were available for the COVID-19 cohort and the AHT control cohort, but not
for the HC from Bruker.

214 Quality control, Statistics and Data illustration

215 To increase the quality of the NMR data set, the above-mentioned quality control reports of the

216 individual samples were checked and a total of 26 samples were sorted out based on these, mainly

217 due to a linewidth of > 2.3 Hz. This resulted in a total 509 samples from 329 COVID-19 patients and

218 58 samples from 58 hypertension patients were investigated.

219 The software package MetaboAnalyst 5.0 was used for statistical analysis of the obtained 220 quantitative NMR reports. To change the data as little as possible, no normalization or scaling has 221 been applied as NMR measurements are highly reproducible and results are based on absolute 222 quantification. Only log transformation was performed to correct for heteroskedasticity. Features 223 with > 50% missing values have been removed. The other missing values were estimated with k-224 nearest neighbors (KNN) based on similar features. As univariate test method, volcano plots, which 225 corresponds to a combination of unpaired t-test and fold change (FC) analysis, were used to 226 determine significant alterations of metabolites and lipoproteins. Thereby a p-value threshold of < 227 0.05 and FC threshold of 1.2 were set. For false discovery rate (FDR) control, Benjamini- Hochberg 228 procedure was used. For multivariate statistics, unsupervised principal component analysis (PCA) was 229 performed to get an overview of the clustering and to identify outliers. Features such as the 2D 230 scores plots, loadings plots, and biplots were used for this purpose. For Table 4, the Biomarker 231 analysis was used to elaborate the most prominent alterations of the respective comparisons. From 232 all significant metabolites, lipoproteins, and laboratory parameters in the volcano plot analyses, 233 those 15 with the highest area under the curve (AUC) were chosen and are listed in Table 4.

- 234 Plots of multivariate statistics were used from MetaboAnalyst 5.0. Further, violin plots and volcano
- plots included in this article were created with GraphPad Prism 9. The consort diagram (Fig 1) was
- created with Microsoft PowerPoint 2019.
- 237 Results
- 238 Cohort composition
- 239 The main characteristics of the Coronataxi cohort are shown in Table 1. As this cohort was divided in
- a normotensive and hypertensive COVID-19 patient group, some characteristics for these are listed
- separately in Table 2, along with the AHT control cohort.
- 242 Table 1. Characteristics of the COVID-19 cohort in total and sample collection

Characteristics	Total	Female	Male
Gender, no. (%)	329	174 (52.9)	155 (47.1)
Age, median (IQR)	54 (44- 64)	52 (41- 63)	58 (48- 65)
BMI, median (IQR)	27.9 (24.4- 32.2)	26.7 (22.6- 32)	29 (25.9- 32.3)
Hospital treatment, no. (%)	71 (21.6)	25 (7.6)	46 (14)
Death, no. (%)	5 (1.5)	3 (0.9)	2 (0.6)
Arterial hypertension (%)	134 (40.7)	63 (19.1) 71 (21.6)	
	Medication (a	ntihypertensives)	
Beta-blockers (%)	61 (18.5)	31 (9.4)	30 (9.1)
Calcium channel blockers (%)	32 (9.7)	14 (4.3)	18 (5.5)
ACE- inhibitors (%)	43 (13.1)	17 (5.2)	26 (7.9)
AT1-R-blockers (%) 62 (18.8)		34 (10.3)	28 (8.5)
	Sample co	llection period	
Timepoint of collection	1	2	3
Numbers of samples	319	137	53
Days after symptom onset, median (IQR)	7 (5-9)	10 (8-12)	11 (10-14)

243The characteristics of the COVID-19 cohort are separated by gender. Besides information about anthropometrics, age and244hospitalization, arterial hypertension (AHT) as the most important pre-existing condition in this work and the

nosticalization, alterial hypertension (AHT) as the most important pre-existing condition in this work and the

antihypertensive treatment are listed. Other pre-existing diseases and medication are listed in the supplementary data S1

Table. In some cases, multiple samples were collected per patient at a maximum of three time points. These are also given in

- 247 the table together with the mean time interval after symptom onset in days. IQR = interquartile range, BMI = body mass
- 248 index, ACE = Angiotensin- converting- enzyme, AT1-R = Angiotensin-1 receptor.
- 249 Table 2. Characteristics of the COVID-19 cohort, separated by regular blood pressure and AHT, and the AHT control cohort

Characteristics	COVID- 19 regular BP	COVID- 19 AHT	AHT control cohort	
Total	195	134	58	
Gender, no. (%):				
Female	111 (56.9)	63 (47.0)	29 (50)	
Male	84 (43.1)	71 (53.0)	29 (50)	
Age, median (IQR)	49 (37- 60)	62 (53- 69)	57 (52- 61)	
Hospital treatment, no. (%)	38 (19.5)	33 (24.6)	n.a.	
CRP, median (IQR)	18.1 (8.7- 48.4)	21.3 (8.3- 57.8)	0.4 (0.1- 1.2)	

- 250 This table presents the relevant characteristics of the COVID- 19 cohort with regular BP and AHT, as well as the AHT control
- 251 cohort. Listed are the total patient numbers, gender, age, hospitalization, and the laboratory parameter C-reactive protein
- 252 (CRP). BP =blood pressure, AHT= arterial hypertension, IQR= interguartile range.

Antihypertensives	Total (%)	Female (%)	Male (%)	Male (%)	
Beta-blockers (%)	42 (72.4)	21 (36.2)	21 (36.2)		
Calcium channel	22 (37.9)	11 (19)	11 (19)		
blockers (%)					
ACE- inhibitors (%)	24 (41.4)	14 (24.1)	10 (17.2)		
AT1-R-blockers (%)	31 (53.4)	15 (25.9)	16 (27.6)		

253 Table 3: Antihypertensive treatment of the AHT control cohort

254 This table shows the antihypertensive treatment with the four substance classes beta- blockers, calcium channel blockers,

255 ACE- inhibitors, AT1-R-blockers of the 58 patients in the AHT control cohort. ACE = Angiotensin- converting- enzyme, AT1-R = 256 Angiotensin-1 receptor.

257 Overview of the performed analyses and results

- 258 In this work, NMR data from a healthy cohort (n= 305) were compared with NMR data of the COVID-
- 259 19 cohort in total (n= 509). Further, NMR data and laboratory parameters of COVID-19 affected
- individuals with AHT (n=216) were compared with an AHT control cohort (n=58) to investigate the 260
- 261 impact of AHT on previous findings on metabolomic, lipoproteomic and inflammatory changes in
- 262 COVID-19 patients. These comparisons were additionally analyzed separately by gender. NMR data
- 263 and laboratory parameters were also analyzed from COVID- 19 patients with AHT (n=216) and
- 264 without (n= 293). The same was performed with samples of hospitalized COVID-19 patients, of which
- 33 individuals (sample n=56) suffered from AHT, while 38 patients (sample n=71) had a regular blood 265
- 266 pressure. Last, AHT patients with different antihypertensive treatment were compared. An overview
- of all performed analyses is given in Fig 1. 267

All rights reserved. No reuse allowed without permission.



268

269 Fig 1. Consort diagram showing an overview of the cohorts

Presented are patient and sample numbers, which were used for the various analyses. HC= Healthy control, AHT= Arterial
 hypertension, BP= Blood pressure, RAASI= Renin- angiotensin- aldosterone- system inhibitors.

272 hypertension, br – blood pressure, haasi- kenni- angiotensin- aldosterone-system milliblois.

273 Table 4 is intended to provide an overview of the results of the individual univariate analyses.

274 Regardless of gender and prior AHT (columns 1, 4, 5), all COVID-19 patients showed an increase in

275 CRP, decreases in alanine, glutamine, lysine, pyruvate, and in the lipoprotein subgroups H4A1, H4CH,

and H4PL. Other common features not included in this presentation, due to a smaller AUC but still

277 showing significant changes in univariate statistics, were an increase in Glyc/SPC ratio, decreased

278 levels of citric acid, isoleucine, and leucine, as well as HDL- subgroups H4A2 and H4FC, total

279 cholesterol (TPCH), total apolipoproteins (TPA1, TPA2), and SPC. Interestingly, COVID-19 groups had

280 decreased leukocyte counts in contrast to the control group. There were differences of laboratory

- 281 parameters in COVID-19 affected depending on gender (column 2). This included higher levels of
- 282 creatinine, ferritin, gamma-glutamyl transferase (GGT) and blood urea nitrogen (BUN) in males. It
- 283 was also noticeable that men had higher inflammatory parameters in the form of Glyc/SPC. The
- 284 branched chained amino acids (BCAA) leucine and valine were increased in men. HDL subclasses

285	(HDL-1, -2, -3) were decreased. When COVID-19 + AHT affected women and men were compared
286	(column 3), there were some changes. In this subgroup, the BCAAs leucine and isoleucine were
287	increased in male patients, but the changes in lipoproteins now concerned LDL subgroups (mainly
288	the larger particles LDL-1 and -3), which showed lower levels in men than in women. When COVID-19
289	patients with normal blood pressure and AHT were compared (column 6), metabolic markers
290	associated with AHT were conspicuous in the hypertensive COVID-19 group. These included elevated
291	creatinine and BUN, a triglyceride-rich lipoprotein profile (IDTG, TPTG, VLTG, VLDL-1, -2), and the
292	intestinal metabolite trimethylamine-N-oxide (TMAO). The last mentioned was found to be elevated
293	only in the COVID-19 + AHT group. Hospitalized hypertensive COVID-19 patients (column 7), also
294	showed a triglyceride-rich lipoprotein profile compared with hospitalized normotensive COVID-19
295	patients. This was characterized by increased total and VLDL triglycerides (TPTG, VLTG), VLDL
296	particles (VLAB, VLDL-1, VLDL-2, VLDL-3), and, in contrast to the whole COVID- 19 + AHT group, also
297	by an increase in HDL triglycerides (HDTG, H1TG, H2TG, H3TG). All group comparisons discussed
298	here, as well as additionally the comparison of the whole COVID-19 cohort with Bruker's HC and the
299	comparison of different antihypertensive treatment groups, will be discussed in detail in the next
300	chapters.

301 Table 4. Overview of results of the individual group comparisons in the univariate st	t atistics
---	-------------------

Parameter	1. COVID- 19 + AHT vs. AHT	2. COVID- 19: Male vs. Female	3. COVID- 19 + AHT: Male vs. Female	4. Female: COVID-19 + AHT vs. AHT	5. Male: COVID-19 + AHT vs. AHT	6. COVID- 19: AHT vs. Regular BP	7. Hospitalized COVID-19: AHT vs. Regular BP
Alanine	0.75↓****			0.73↓****	0.76↓****		
BUN		1.45 <mark>个****</mark>	1.57个****			1.39 <mark>个****</mark>	
Citric acid	0.69↓****						
Creatine							0.46 🗸*
Creatinine		1.44 个****	1.43个****			1.22	1.35 个***
Creatinine.lab		1.47个****	1.61个****			1.24个****	1.51 个***
CRP	4.41			4.37	4.27 个****		
Dimethylsulfone						0.52↓**	
Ferritin		3.11 个****					
Formic acid	0.48↓****				0.44↓****		
GGT		2.16 个****					
Glutamine	0.75↓****			0.78↓****	0.73↓****		

1.26个****

0.73↓**** 0.7↓****

0.74

0.74

0.73

0.83↓****

0.8↓****

1.23

0.76↓****

0.74

0.71

0.75↓****

0.83↓****

0.70↓****

0.64

0.34↓****

0.76↓****

0.82↓****

Glyc/SPC H1A1

H1A2

H1CH

H1FC

H1PL H1TG

H₂CH H2TG

H3FC H3TG

H4A1

H4A2

H4CH

H4PL

HDA1

HDA2

HDCH HDTG

IDTG

L1AB

L1CH

L1FC

L1PL

L1PN

L3AB L3CH

L3FC

L3PL

L3PN

Leuk

Lysine

SPC

TPA1

TPA2

TPCH

TPTG

TMAO

V1CH

V1PL

V1TG

V2FC

V2TG

Methionine

Pyruvic acid

Leucine

Isoleucine

perpetuity. All rights reserved. No reuse allowed without permission.

1.28 *** 0.82

0.8↓****

0.82↓***

0.81 \[****

0.82↓****

0.78↓**

0.76 /***

0.8↓**

0.78↓** 0.79 \/**

1.35 ****

1.46

0.76

0.72

0.71

0.75

0.66↓****

0.71↓***

0.64

0.72

0.34

0.73↓****

0.77

0.72↓****

0.76↓****

0.80↓****

0.83↓****

0.77↓****

0.67↓****

0.63

0.34↓****

0.73

0.79↓****

0.80↓****

1.30 **

1.26 **

1.23 **

1.23 **

1.31 **

1.48 1*

1.43 **

1.45 *****

1.43 **^***

1.43 ***

0.79 \/***

0.82

1.22

1.25 * 1.31

1.34 1***

1.34 *******

1.23个**

1.23 ***

14

medRxiv preprint doi: https://doi.org/10.1101/2022.12.20.22283729; this version posted December 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

All rights reserved. No reuse allowed without permission.

V3FC				1.45 个*
Valine	1.2个****			
VLAB				1.23 ↑*
VLTG			1.26个***	1.34 ↑*

This table gives an overview of the performed univariate analyses. These comparisons are further elaborated below and illustrated in volcano plots. The number indicated is the fold change. The arrow indicates whether a metabolite, lipoprotein or laboratory value was found to be decreased (blue) or increased (red) in the group marked in red, respectively. The p-value is indicated in form of asterisks (p < 0.05 (*), p < 0.01 (**), p < 0.001 (***)). Since many metabolites were

306 found to be significant in individual comparisons, the 15 that also showed the highest area under curve (AUC) in the

307 Metaboanalyst 5.0 biomarker analysis were selected for this presentation. AHT= Arterial hypertension, BP= Blood pressure,

308 BUN= Blood urea nitrogen, Creatinine.lab= Creatinine value from laboratory report, CRP= C-reactive protein, GGT= Gamma-

- 309 glutamyl- transferase, Leuk= Leukocytes count, TMAO= Trimethylamine-N-oxide.
- 310

311 Differences in the metabolomic phenotypic when comparing total COVID-19 patient cohort with

312 sub-cohort of patients with hypertension

313 For comparison with previously reported findings of NMR-based alterations of metabolites and 314 lipoproteins, a volcano plot analysis was performed comparing the 305 samples of the HC with the 315 entire Coronataxi COVID-19 cohort, i.e., 509 samples. All metabolic changes named below therefore 316 apply to the comparison of the entire COVID-19 cohort with Bruker's HC and can be seen in the 317 volcano plot in Fig 2A. In this plot, 60 metabolites and lipoproteins were decreased more than 1.2-318 fold, whereas 29 were increased. The metabolic changes largely coincided with the literature already 319 cited in the introduction. A triglyceride-rich lipoprotein profile could be detected in the total COVID-320 19 cohort based on the elevated levels of total plasma triglyceride (TPTG), other triglyceride 321 subgroups (IDTG, L1TG), all major VLDL groups (VLAB, VLPN, VLCH, VLFC, VLTG, and VLPL), and 322 several VLDL subgroups (e.g. V1TG, V2CH, V3TG, V5FC, for example) in all sizes except VLDL-4. On the 323 other hand, a reduction in total plasma apolipoproteins A1 and A2 and all major HDL- groups (HDA1, 324 HDA2, HDCH, HDFC, HDPL), except HDTG, was observed in the COVID-19 cohort. All four sizes were 325 present, with HDL-3 and -4 as the most significant subgroups, of which the apolipoprotein, 326 phospholipid, and cholesterol subgroups were particularly represented. Furthermore, total plasma 327 cholesterol (TPCH), several LDL major (LDCH, LDFC, LDPL), and subgroups, were shown to be 328 decreased, this being mainly true for denser LDL subgroups (LDL-3, -4, -5, -6), as well as for the 329 phospholipid and cholesterol subgroups (e.g., L4CH, L5PL, L6FC). For metabolites, we observed a 330 decrease over 1.2-fold in several amino acids, including glutamine, lysine, histidine, leucine, and

331 isoleucine. Another reduced metabolite was citric acid. In contrast, ketone bodies (3-

332 hydroxybutyrate, acetone), the amino acids phenylalanine and glutamic acid, and the metabolites

333 succinic acid and dimethylglycine were increased in the COVID-19 cohort.

334 To see whether the results described above could be reproduced when stratifying for AHT, the 335 COVID-19 cohort was divided into a hypertensive and a normotensive sub-cohort. The COVID-19 336 cohort with AHT was compared with an AHT control group without COVID-19 using another volcano 337 plot (Fig 2B). We could identify 60 metabolites, lipoproteins, and laboratory parameters which 338 showed a decrease of more than 1.2 -fold in the COVID-19 + AHT cohort (as in the previous 339 comparison), while 5 showed an increase (versus 29 increased features in the comparison COVID-19 340 in total vs. HC). The main differences between those two comparisons were that we could not 341 observe a triglyceride-rich lipoprotein profile in the COVID-19 + AHT cohort. Only the inflammatory 342 parameters CRP and Glyc/SPC ratio, the amino acids glutamic acid and phenylalanine, and the citrate 343 cycle metabolite succinic acid were elevated. The above-described increase in ketone bodies did not 344 show up in the COVID-19 + AHT group. Furthermore, the significant reductions in HDL- fractions in COVID-19 + AHT patients were mainly concentrated on HDL-4 particles (H4A1, H4A2, H4CH, H4FC, 345 346 H4PL), in contrast to the whole COVID-19 group. On the other hand, there were some features, 347 which these two comparisons had in common, including decreases in amino acids lysine, glutamine, 348 histidine, leucine, and isoleucine in the SARS-CoV-2 infected patients with and without AHT. In the 349 COVID-19 + AHT cohort, additionally, the amino acids alanine, methionine, and tyrosine were 350 decreased. Another common metabolite was citric acid, which showed decreased levels in COVID-19 351 patients in total and in COVID-19 + AHT. As in the whole COVID-19 cohort, also in the hypertensive 352 group, a reduction of TPCH and several LDL- major- (LDAB, LDCH, LDFC, LDPL) and subgroups could 353 be observed. Again, mostly denser particles (LDL-4, -5, -6) and phospholipid and cholesterol fractions 354 of LDL were present. Interestingly, a few major VLDL groups (VLFC, VLPL, VLTG) and isolated VLDL-1 355 particles were also reduced in the COVID-19 + AHT cohort.

All rights reserved. No reuse allowed without permission.



356

Fig 2. Univariate comparisons by means of volcano plots showing the differences of the metabolome and lipoproteome in COVID-19 + AHT patients compared to the COVID-19 cohort in total

FC > 1.2, p < 0.05, FDR < 0.01: The red features are significantly increased in the COVID-19 cohorts, respectively, while the
 green ones are significantly decreased in COVID-19 affected. The features in red boxes showed up repeatedly in these and
 following comparisons and were therefore typical altered in COVID-19 patients. (A) shows the comparison between the
 COVID- 19 cohort in total with the HC. (B) shows the comparison between hypertensive COVID-19 patients and uninfected
 hypertensive individuals. In (C) and (D) violin plots show the decreased respectively increased NMR parameters with the
 highest significance for each comparison. The y-axis shows the normalized concentration. HC= Healthy control, AHT= Arterial

- 365 *hypertension, Cov= COVID-19, CRP= C- reactive protein, Leuk= Leukocytes count.*
- 366 367

368 Gender differences in COVID-19 patients with and without AHT

369	In Fig 3A, a volcano plot was used to compare 155 (254 samples) male and 174 (255 samples) female
370	COVID-19 patients from the cohort in total. Overall, 26 features were significantly increased in male
371	COVID-19 patients, whereas 19 were decreased. Some gender-specific laboratory parameters were
372	altered, such as creatinine, blood urea nitrogen (BUN), ferritin, and the liver values GGT and GOT,
373	which showed higher values in men than in women. Furthermore, males with COVID-19 showed
374	higher levels of Glyc/SPC ratio, BCAAs leucine, isoleucine, and valine, ketone bodies (acetones,
375	acetoacetic acid, 3-hydroxybutyric acid), and various VLDL- subgroups, including triglyceride (VLTG,
376	V1TG, V2TG), phospholipid (V1PL, V2PL, V3PL), and cholesterol (V1FC, V1CH, V2FC, V2CH, V3FC)
377	fractions. In comparison, women showed higher values in HDL- subgroups. This was true for
378	apolipoprotein (H1A1, H1A2), cholesterol (H1CH, H1FC, H2CH, H2FC, H3FC), phospholipid (H1PL), and
379	triglyceride fractions (H1TG). HDL-4 did not stand out in the gender comparison. Furthermore, LDL
380	particles were more abundant in female COVID-19 patients. Among them were the larger LDL-
381	subgroups, like LDL- 1 (L1CH), LDL-2 (L2CH, L2PL), and LDL-3 (L3AB, L3CH, L3FC, L3PN, L3PL).
382	To examine the effect of AHT on metabolic sex differences in COVID-19 patients, the COVID-19 + AHT
383	cohort was divided by sex. A volcano plot was performed with data from 124 samples from 71 men
384	and 92 samples from 63 women with COVID-19 + AHT (Fig 3B). This comparison in the AHT subgroup
385	revealed less significant differences than present in the total COVID-19 cohort. 10 features (vs. 26 in
386	the male COVID-19 group in total) were significantly increased in males compared to females; 15
387	features (vs. 19 in the male COVID-19 cohort in total) were decreased in male patients. The
388	triglyceride-rich lipoprotein profile of men now was less pronounced, only isolated VLDL particles
389	were elevated (V2FC, V2PL, V3PL). Ketone bodies no longer stood out as significant, nor did the
390	Glyc/SPC ratio. Men showed higher levels of the BCAAs leucine and isoleucine, as well as citric acid,
391	and dimethyl sulfone. Women continued to show higher values in the LDL fractions, but not in the
392	HDL particles. Among them, LDL-1 (L1AB, L1CH, L1FC, L1PL, L1PN), LDL-2 (L2AB, L2PL), LDL-3 (L3AB,
393	L3CH, L3FC, L3PL, L3PN), and LDL-4 (L4FC) were present.

394 The comparisons of COVID-19 + AHT with an AHT control group, as well as the gender comparisons, 395 identified characteristics that are independent of gender and prior AHT disease and thus typical of 396 COVID-19 infection in our cohort. These are shown as outlined in red in Fig 2 and 4. In the volcano 397 plots, male and female hypertensive patients with and without COVID-19 were compared. There 398 were 29 samples from 29 female hypertensive patients without COVID-19 and 92 samples from 63 399 female hypertensive patients with COVID-19 and AHT. In male patients, 29 samples from 29 400 hypertensive patients without and 124 samples from 71 patients with COVID-19 and AHT were also 401 compared. In these analyses, metabolites and lipoproteins that were also apparent in the previous univariate statistics stood out. These included an increase in Glyc/SPC, glutamic acid and CRP, and a 402 403 decrease in amino acids leucine, isoleucine, glutamine, and lysine, citric acid, and HDL-4 fractions 404 (H4A1, H4A2, H4CH, H4FC, H4PL), total cholesterol (TPCH), and SPC.

All rights reserved. No reuse allowed without permission.



406

407 Fig 3. Univariate comparisons by means of volcano plots showing gender differences of COVID-19 patients with and with-408 out AHT

409 FC > 1.2, p < 0.05, FDR < 0.01: The red features are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green ones are significantly increased in men, respectively, while the green o

410 nificantly decreased in men, compared to women. (A) shows the comparison between the genders in the COVID- 19 cohort in

411 total. (B) shows the comparison between the genders in the COVID-19 + hypertension cohort. In (C) violin plots show the

412 decreased respectively increased NMR parameters with the highest significance. In (D) the left violin plot shows L1CH, as the

413 lipoprotein with the highest significance, which is decreased in males. The right violin plot shows leucine, as increased NMR

414 parameter in males, with the second highest significance after creatinine. The y-axis shows the normalized concentration.

415 AHT= Arterial hypertension, BUN= Blood urea nitrogen, Creatinine.lab= Creatinine from laboratory report, GGT= Gamma-

416 glutamyl- transferase, GOT= Glutamate- oxalacetate- transferase, F= Female, M= Male.

All rights reserved. No reuse allowed without permission.



417

418 Fig 4. Univariate comparison of AHT cohorts with and without COVID-19, separated by gender, respectively

FC > 1.2, p < 0.05, FDR < 0.01: The red features are significantly increased in COVID-19 patients, while the green ones are
 decreased. Plot (A) shows the comparison of AHT vs. AHT + COVID-19 for females, plot (B) shows this comparison for male
 gender. Features in red boxes are common in both genders and in COVID-19 affected considering AHT. AHT= Arterial hyper tension, Creatinine.lab= Creatinine from laboratory report, CRP= C-reactive protein, 3-HBA= 3- Hydroxybutyric acid.

423

424 Hypertensive COVID-19 patients show NMR-based metabolomic and lipoproteomic characteristics

- 425 of an increased cardiovascular risk
- 426 The aim of the next analysis was to compare hypertensive and normotensive COVID-19 patients to
- 427 investigate if there are metabolic alterations between those two groups which could indicate a
- 428 higher risk for a severe COVID-19 disease course. 216 samples from 134 hypertensive COVID-19
- 429 patients were compared with 293 samples from 195 normotensive COVID-19 patients. A volcano plot

430 (Fig 5) was performed, where 15 metabolites, lipoproteins, and laboratory parameters were increased more than 1.2- fold. Two lipoprotein subclasses (L3CH, L3PL) and one metabolite 431 432 (dimethyl sulfone) were reduced. The highest significant alterations were seen in the elevated renal 433 values in the hypertensive COVID-19 group. BUN and creatinine.lab corresponded to standard 434 laboratory parameters, whereas creatinine was part of the NMR-based B.I. QUANT-PS report. In 435 addition, significant increases in triglyceride-rich VLDL particles were observed, especially in the 436 larger and less dense subgroups (VLDL-1, -2, -3), as well as in the triglyceride subfractions (VLTG, 437 V1TG, V2TG). Total plasma triglyceride (TPTG) and IDL triglyceride fraction (IDTG) also showed 438 elevated levels. Regarding metabolites, the citrate cycle metabolite succinic acid was increased, as in 439 other analysis. The metabolite trimethylamine-N- oxide (TMAO), which is produced by intestinal

440 bacteria and is considered a cardiovascular risk marker, only stood out in this analysis.

All rights reserved. No reuse allowed without permission.





442 Fig 5. Metabolomic differences in normotensive and hypertensive COVID-19 patients

In (A) univariate analysis by means of volcano plot showing significant differences in normotensive and hypertensive COVID19 patients (FC > 1.2, p < 0.05, FDR < 0.01): The red features are increased in the COVID-19 + AHT cohort, while the green
ones are decreased in COVID-19 + AHT. (B) Multivariate analysis by means of principal component analysis (PCA) showing
the distribution of both groups. (C) Violin plots showing significant alterations of the cardiovascular risk marker trimethylamine-N-oxide (TMAO) and TPTG. The y-axis shows the normalized concentration. AHT= Arterial hypertension, BP = blood
pressure, BUN = Blood urea nitrogen, Creatinine.lab = Creatinine from laboratory report, Cov = COVID-19.

- 450 Similar metabolic alterations were observed in hospitalized COVID-19 + AHT patients (Fig. 6). This
- 451 group also showed elevated renal values (BUN, creatinine) and a triglyceride-rich lipoprotein profile
- 452 compared with normotensive hospitalized COVID-19 patients. However, the lipoprotein subclass
- 453 distribution differed from the COVID-19 + AHT group in total in that HDL triglycerides were elevated
- 454 in the hospitalized COVID-19 + AHT group. These subgroups were not conspicuous in the previous
- 455 comparison (Fig. 5).

In particular, another volcano plot analysis was performed with 56 samples from 33 hospitalized 456 457 COVID-19 + AHT patients and 71 samples from 38 normotensive hospitalized COVID-19 patients (Fig 458 6). Hereby, 17 features were elevated more than 1.2-fold, one metabolite (creatine) was decreased. 459 Also, in this comparison, creatinine and BUN showed the highest significant alterations. The 460 lipoprotein profile of the hospitalized COVID-19 + AHT cohort was characterized by increased total 461 triglycerides and triglyceride subfractions (TPTG, VLTG, IDTG), increased VLDL particles in the total 462 (VLPN), and in the less dense subfractions (VLDL-1, -2, -3). In addition, all HDL- triglyceride 463 subfractions (HDTG, H1TG, H2TG, H3TG), except H4TG, were elevated in the hospitalized,

464 hypertensive COVID-19 cohort.



466 Fig 6. Metabolomic characteristics of hospitalized COVID-19 patients with AHT

467 In (A) univariate analysis by means of volcano plot showing significant differences between normotensive and hypertensive 468 hospitalized COVID-19 patients (FC > 1.2, p < 0.05, FDR < 0.01): The red points show increased features in the hospitalized 469 COVID-19 + AHT cohort, while the green one is decreased. (B) Multivariate analysis by means of principal component analy-470 sis (PCA) showing the distribution of both groups. In (C) violin plots show the most significant alterations of the NMR param-471 eter Creatinine and H3TG. The y-axis shows the normalized concentration. AHT= Arterial hypertension, BP= blood pressure, 472 hosp = hospitalized, BUN= Blood urea nitrogen, Creatinine.lab= Creatinine from laboratory report.

473

474 Of the 134 hypertensive COVID-19 affected patients, 120 were treated with antihypertensives. 48 of 475 these were treated with one medication, 72 with two or more. An overview of the medications of the 476 hypertensive patients was given in Table 1. Antihypertensives indicated were angiotensin-converting-477 enzyme inhibitors (ACEI), angiotensin-1 receptor blockers (AT1RB), beta-blockers (BB), and calcium 478 channel blockers (CCB). To determine any medication differences in metabolites and lipoproteins, 479 the COVID-19 + AHT cohort was divided into subgroups according to their antihypertensive 480 treatment. Patients treated with ACEI and/or AT1RB alone were grouped as the renin-angiotensin-481 aldosterone system inhibitor (RAASI) group, which included 75 samples. Hypertensive patients treated with BB and/or CCB formed the no RAASI group, which included 40 samples. The majority in 482 483 this group were treated with BB (29 samples). 75 samples were from patients treated with different 484 combinations of ACEI/AT1RB and BB and/or CCB. The 26 samples from patients who were not taking 485 antihypertensives according to metadata were excluded from this analysis. The groups were 486 compared with univariate operations. Here, the RAASI- group showed improved renal values 487 compared with the no RAASI group, in terms of decreased creatinine levels and higher glomerular 488 filtration rate (GFR). This was not observed when patients were treated with a combination of RAASI 489 and BB or CCB. In general, no significant alterations could be seen in the comparison of a 490 combination of RAASI with BB/CCB versus the no RAASI group. Interestingly, increased VLDL particles

491 (VLPN), consisting of the denser subgroups VLDL-4, were observed in the RAASI group. All significant

492 changes are shown in the volcano plot in Fig 7.



493



In (A) univariate comparison by means of volcano plot analysis (FC > 1.2, p < 0.05, FDR < 0.01): The red features correspond
 to increased values in the RAASI group, while the green ones correspond to decreased values. (B) Multivariate analysis by
 means of principal component analysis (PCA) showing the distribution of both groups. (C) Violin plots show significant alter ations in the kidney parameters Creatinine and GFR = glomerular filtration rate. The y-axis shows the normalized concentra tion. Creatinine.lab= Creatinine from laboratory report.

501

502 Hypertensive COVID-19 patients show higher inflammatory parameters

- 503 As a further univariate test method, an unpaired t-test was performed with the cohorts AHT versus
- 504 COVID-19 + AHT. Another unpaired t-test was performed for the comparison COVID-19 with AHT
- versus regular BP. The p-value threshold was set at 0.05 (FDR < 0.01). These t-tests were performed
- 506 for the already mentioned typical altered metabolites (glutamine, isoleucine, leucine, lysine, citric

507 acid) and lipoproteins (HDL-4, TPCH, LDCH, SPC) in COVID-19 patients. The results are shown using 508 violin plots in the supplementary data S20. It was additionally observed that hypertensive COVID-19 patients showed higher inflammation levels than normotensives. This was true for the NMR 509 510 parameters Glyc, as well as the Glyc/SPC ratio, with the hypertensive COVID-19 group showing 511 significantly higher values with p-values of p= 0.0014 for Glyc and p= 0.0058 for Glyc/SPC ratio. SPC 512 was decreased in normotensive COVID-19 patients compared to the cohort without COVID-19 and therefore did not stand out as significant in this comparison, same for the laboratory value CRP, 513 514 which was increased in normotensive and hypertensive COVID-19 patients. Violin plots for the 515 mentioned inflammatory parameters are shown in Fig 8.

516



517

518 Fig 8. COVID-19 patients with AHT show higher inflammatory NMR parameters

519Violin plots showing the inflammatory NMR parameters Glyc/SPC (A), SPC (B), Glyc (C), and routine lab CRP (D). Unpaired t-520tests were performed for the comparison of AHT versus COVID-19 + AHT, and COVID-19 with and without AHT. Significant521alterations are shown in form of asterisks: ns (not significant), p < 0.05 (*), p < 0.01 (**), p < 0.001 (**), p < 0.0001 (**). The522y-axis shows the normalized concentration. AHT= Arterial hypertension, Cov= COVID-19, BP= Blood pressure, CRP= C-reactive523protein.

524

525 Discussion

- 526 In this study, we analyzed a COVID-19 cohort with 509 serum samples from 329 patients, which were
- 527 treated mainly in an outpatient care setting. In our analyses, we focused on 134 patients (216
- 528 samples), which were additionally affected by arterial hypertension. To the best of our knowledge,

this is the first study to investigate the effect of AHT on COVID-19 in the context of NMR- based
metabolomics. We could show that the metabolic changes of COVID-19 disease behave differently
when pre-existing AHT is considered. Stratification for AHT has also an impact on differences
detected between genders. Furthermore, it became clear that hypertensive COVID-19 patients might
at higher risk for complications, shown by certain changes in lipoproteins, metabolites, and
inflammatory parameters.

535 The Coronataxi study took place in Germany, where, according to the Robert-Koch-Institute, AHT 536 prevalence is about one-third in women and men, respectively. In subjects older than 65 years 537 prevalence is even two third for both genders. In our COVID-19 cohort AHT was also very present 538 with 40.7%. Previously it has been shown that individuals with pre-existing cardiovascular disease 539 have an altered metabolic profile, particularly with respect to lipoproteins. These include, among 540 others, increased VLDL particles and decreased HDL levels (31, 35). Since hypertensive patients may 541 thus have elevated VLDL levels, they obviously drop out in the univariate statistics when COVID-19 542 patients with hypertension are compared with controls with hypertension, leading to the hypothesis 543 that COVID-19, at least in milder courses, does not cause an increase in VLDL and its subgroups, as 544 well as in the ABA1 ratio. However, what does suggest dyslipidemia in COVID-19-affected individuals 545 despite this are the decreased levels in the HDL fractions. In particular, the decreased levels in the 546 dense HDL-4 particles are considered typical of COVID-19 in our cohort. HDL appears to correlate 547 inversely with cardiovascular risk (36). However, there are discrepancies in the extent to which the 548 various HDL subgroups are involved in this process (37). Furthermore, since different methods are 549 used to measure HDL subgroups, it is not always easy to compare the literature in this regard. Small 550 HDL particles, such as HDL-4 (corresponding to HDL-3 in ultracentrifugation (38)), have been shown 551 in some studies to be risk factors for cardiovascular disease (39). On the other hand, the protective 552 and antioxidant effects on the endothelium (40) and the fibrinolytic properties of denser HDL 553 particles had been described. (41). Apolipoproteins A1 and A2 each play a major role, as well as 554 inverse correlating markers for cardiovascular risk (42). Adjacent to cardiovascular disease, HDL has a

555 more clear relationship with the immune system (43, 44) and changes in its composition and function 556 during an acute phase reaction (45). This is characterized by a decrease in apolipoprotein A1 and HDL 557 cholesterol, which was evident in our COVID-19 cohort where we identified a decrease in total (TPA1 558 and TPCH, respectively) and HDL groups HDA1 and H4A1, and HDCH and H4CH, respectively. Thus, it 559 can be inferred that the acute-phase response induced by COVID-19 may cause dysfunctionality of 560 HDL particles, leading to loss of atheroprotective properties (46). In addition to the decrease in HDL-561 particles, several LDL- fractions also showed a decrease. This is consistent with other studies (8, 14). 562 Furthermore, a correlation between increasing disease severity and a decrease in LDL cholesterol, as 563 well as an inverse correlation between LDL cholesterol and CRP could be observed (47, 48). Possible 564 reasons for this include impaired liver function, altered lipid metabolism under the influence of

565 cytokines, and the breakdown of lipids by free radicals (47).

566 General metabolic differences in COVID-19 patients

567 Regarding metabolites, COVID-19 characteristics include decreases in amino acids glutamine,

568 isoleucine, leucine, and lysine. This indicates an altered energy metabolism in the course of

569 hypoxemia (49). Decreased glutamine correlated inversely with CRP, lactate dehydrogenase (LDH),

570 and partial pressure of oxygen in this study (49). In addition, glutamine fulfills important functions in

571 the body, e.g. as a reactant for glutathione biosynthesis or as an energy supplier for immune cells

- 572 (50). The reduction in the other amino acids mentioned could indicate increased amino acid
- 573 catabolism, possibly as a result of temporary fasting during acute infection, as of our COVID-19
- 574 cohort, 22% reported loss of appetite and 9% nausea. Another metabolite that is decreased in

575 COVID-19 is citric acid. This Krebs cycle metabolite also correlated inversely with CRP and LDH in one

576 study (51).

577 The role of AHT on previous findings

578 Comparing the AHT- control cohort with the COVID-19 + AHT cohort, the acute phase protein CRP
579 showed an increase, which is not surprising, as well as the NMR-based inflammatory parameter

580 Glyc/SPC. This ratio was also elevated in another study of COVID-19 patients (28). Glycoproteins 581 (Glyc) represent the acute phase reaction (23). Supramolecular Phospholipid Composite signal (SPC) 582 reproduces lipoproteins, especially apolipoproteins and HDL (28). Another prominent parameter in 583 the COVID-19 cohort was phenylalanine. It has already been mentioned that this amino acid is 584 elevated in COVID-19 patients and also correlates with a more severe progression (17). Even before 585 the COVID-19 pandemic, phenylalanine was shown to be elevated in severe infections and associated 586 with increased mortality, intensive care unit (ICU) treatment, and CRP levels (52). The elevated 587 phenylalanine levels may be related to impaired liver or kidney function, as the hydroxylation of 588 phenylalanine to tyrosine occurs in these organs (53). At the same time, tyrosine levels are reduced 589 in the COVID-19 + AHT cohort, raising further suspicion that this process may be impaired, as it is also 590 the case in patients with severe liver injury (54), and chronic kidney failure (55). The increased levels 591 of glutamic acid in the COVID- 19 patients may result from an increased supply from glutamine, for 592 the synthesis of glutathione as an antioxidant or as an alternative energy resource for 593 gluconeogenesis (56). Furthermore, COVID-19 patients exhibit elevated levels of the Krebs cycle 594 intermediate succinic acid. This is possibly an expression of a hypoxic metabolic state, since succinic 595 acid is able to stabilize hypoxia inducible factor- 1α (HIF- 1α) (57) and also to force the interleukin 596 production (58).

597 Gender differences in COVID-19

598 Male sex is a known risk factor for severe COVID-19 progression and complications (59, 60). In our 599 gender comparison of COVID-19 individuals, several parameters could be identified as markers for an 600 unfavorable disease course. These included elevated ketone bodies (acetone, acetoacetic acid, 3-601 hydroxybutyric acid) and marked dyslipidemia (16). The latter was indicated by increased VLDL 602 particles in males and decreased HDL levels compared to female SARS-CoV-2 infected individuals. 603 From this, one could deduce that the risk factor "male gender" can also be observed in the 604 metabolome. However, a different picture emerged when the AHT factor was also included in this 605 comparison. Only isolated VLDL particles then showed increased values. Ketone bodies, Glyc/SPC and

606 HDL particles were also no longer found to be significantly altered. The sex differences were mainly 607 related to an increase in various LDL fractions in women, as well as an increase in the BCAAs leucine 608 and isoleucine, citric acid, and three VLDL particles. The elevated levels of dimethyl sulfone in our 609 study could be attributed to two patients with very high levels and is possibly the result of a specific 610 diet. However, considering sex and AHT, there were also some common features that, although not 611 specific for COVID-19, emerged as typical metabolic profile in with SARS-CoV-2 infected individuals. 612 These included increases in CRP and Glyc/SPC, and decreases in glutamine, isoleucine, leucine, lysine, 613 citric acid, HDL-4 subsets, total cholesterol, LDL- cholesterol, and SPC. This is consistent with other 614 metabolomics studies (8, 9, 13, 14) on COVID-19 but gives a finer picture of metabolic characteristics.

615 AHT as risk factor in COVID-19: What can be seen in the metabolome?

AHT has also previously been cited as a risk factor for severe COVID-19 progression (4) and is also

617 associated with an increased risk of various cardiovascular complications, such as heart failure or

618 acute coronary syndrome (61). In addition to the already discussed changes in the lipoproteome in

619 cardiac pre-diseased patients, the metabolite trimethylamine-N-oxides (TMAO) should also be

620 mentioned. This metabolite, which is synthesized by intestinal bacteria, is considered a

621 cardiovascular risk marker due to its proartherosclerotic effects. (62).

622 As expected, also in our cohort with mostly milder courses, hypertensive COVID-19 patients showed 623 an increase in the mentioned cardiovascular risk markers compared with normotensive COVID-19 624 affected individuals. Interestingly, the ABA1 ratio did not stand out as significantly elevated in 625 hypertensive patients in our cohort. Furthermore, signs of impaired renal function were clearly 626 observed in hypertensive COVID- 19 patients. However, these markers are less an expression of 627 COVID-19 but rather due to AHT as such. Thus, when comparing the AHT- cohorts with and without 628 COVID-19, there was no increase in these parameters and thus no further deterioration of renal 629 function during acute infection. However, an indication of renal impairment in the COVID-19 + AHT 630 cohort, is the observation that tyrosine was found to be significantly decreased in hypertensives only

631 in the comparison AHT with and without COVID-19. The triglyceride-rich lipoprotein profile also did 632 not appear to be linked to COVID-19. Succinic acid, which was elevated in hypertensives, could 633 represent a more severe COVID-19 course as an expression of a hypoxic metabolic state (57). TMAO, 634 which was increased in hypertensive COVID-19 patients, was also associated with a more severe 635 COVID-19 course in patients with pre-existing diabetes mellitus or cardiovascular diseases in one 636 study (63). Also, COVID-19 patients with pre-existing AHT showed higher inflammatory values in 637 terms of Glyc and Glyc/SPC ratio in our study compared to patients without pre-existing AHT. 638 Comparing hospitalized COVID-19 patients with and without AHT, it was also not surprising that 639 COVID-19 patients with AHT had higher renal values (creatinine, BUN), as well as a lipoprotein profile

641 Influence of various antihypertensives on COVID-19 + AHT patients

642 With regard to antihypertensive treatment, the use of angiotensin converting enzyme inhibitors 643 (ACEI) and angiotensin II receptor blockers (ARB) was discussed at the beginning of the pandemic. It 644 was suspected that these classes of drugs, by increasing the expression of ACE-2 receptors, would 645 lead to increased viral uptake into cells and thus to a worse course of COVID-19 disease (64). 646 However, it has now been shown that treatment with ACEIs and ARBs is not associated with a more 647 severe disease course or increased mortality, but rather the opposite, and blood pressure control is 648 an important factor in COVID-19 treatment (65, 66). Also in our results, COVID-19 + AHT patients, 649 treated with this group of drugs had lower mean levels of renal creatinine and a higher GFR than 650 patients treated with other antihypertensives. However, with the use of RAASI, there was also an 651 increase in some VLDL particles. This could be due to a higher number of multimorbid patients in this 652 group.

653 Conclusion

640

rich in triglycerides.

Here, we presented an NMR-based study examining serum from a large cohort of outpatients and
hospitalized COVID-19 patients. Extensive meta-data allowed us to relate to common laboratory

parameters, as well as to include in our analyses the important comorbidity AHT, which occurs with

high prevalence. This provides a much finer picture of the metabolic fingerprint of COVID-19 disease.

- 658 The extensive quantification of metabolites and lipoproteins with an uncomplicated and rapid
- 659 measurement method such as NMR opens many possibilities in the field of pathophysiology research
- and risk stratification, which has not yet been conclusively elucidated in COVID-19.
- 661 We are aware that the statistical power is diminished by larger differences in cohort sizes and by the
- fact that no comparisons of laboratory parameters and parameter from the B.I. PACS[™] report could
- be included in the comparison of the COVID-19 patient cohort with the healthy control group from

664 Bruker (HC).

665 Funding

666 This project was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research

667 Foundation)- project number 374031971- TRR 240.

668 Acknowledgments

669 We thank the Werner Siemens Imaging Center with the Chair of Department Prof. Dr. Pichler for the 670 opportunity to perform this research. In addition, we greatly thank Karin Tarbet from the Coronataxi-671 team for her great work and effort and the medical technicians Petra Klöters-Plachky and Alexandra 672 Hof for their biobanking work. Further, we want to thank the members of CRC/TR240 project Z03 673 (Cornelia Fiessler, Anna Grau, Steffi Jiru-Hillmann, Kirsten Haas) from the institute for clinical 674 epidemiology and biometry, University Hospital Würzburg, Würzburg, Germany and Frederic 675 Emschermann from the Department of Internal Medicine III, Cardiology and Angiology, University 676 Hospital Tübingen, Tübingen, Germany for the good cooperation. We also thank our technical 677 assistants Miriam Owczorz and Daniele Bucci for the support during sample preparation and NMR 678 measurements.

679

All rights reserved. No reuse allowed without permission.

681 **References:**

 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet.
 2020;395(10229):1054-62.
 Scudiero F, Silverio A, Di Maio M, Russo V, Citro R, Personeni D, et al. Pulmonary embolism in

686 COVID-19 patients: prevalence, predictors and clinical outcome. Thrombosis Research. 2021;198:34-687 9.

688 3. Farshidfar F, Koleini N, Ardehali H. Cardiovascular complications of COVID-19. JCI Insight.
689 2021;6(13).

6904.Gao Y-d, Ding M, Dong X, Zhang J-j, Kursat Azkur A, Azkur D, et al. Risk factors for severe and691critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428-55.

5. Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, et al. Gender Differences in Patients With
COVID-19: Focus on Severity and Mortality. Frontiers in Public Health. 2020;8.

- 694 6. Letertre MPM, Giraudeau P, de Tullio P. Nuclear Magnetic Resonance Spectroscopy in Clinical
 695 Metabolomics and Personalized Medicine: Current Challenges and Perspectives. Front Mol Biosci.
 696 2021;8:698337-.
- 697 7. Pang H, Jia W, Hu Z. Emerging applications of metabolomics in clinical pharmacology. Clinical
 698 Pharmacology & Therapeutics. 2019;106(3):544-56.
- Bruzzone C, Bizkarguenaga M, Gil-Redondo R, Diercks T, Arana E, García de Vicuña A, et al.
 SARS-CoV-2 Infection Dysregulates the Metabolomic and Lipidomic Profiles of Serum. iScience.
 2020;23(10):101645.
- 9. Baranovicova E, Bobcakova A, Vysehradsky R, Dankova Z, Halasova E, Nosal V, et al. The
 Ability to Normalise Energy Metabolism in Advanced COVID-19 Disease Seems to Be One of the Key
 Factors Determining the Disease Progression—A Metabolomic NMR Study on Blood Plasma. Applied
 Sciences. 2021;11(9):4231.
- 70610.Dierckx T, van Elslande J, Salmela H, Decru B, Wauters E, Gunst J, et al. The metabolic707fingerprint of COVID-19 severity. medRxiv. 2020:2020.11.09.20228221.

Ghini V, Meoni G, Pelagatti L, Celli T, Veneziani F, Petrucci F, et al. Profiling metabolites and
 lipoproteins in COMETA, an Italian cohort of COVID-19 patients. PLOS Pathogens.

710 2022;18(4):e1010443.

Schmelter F, Foeh B, Mallagaray A, Rahmoeller J, Ehlers M, Lehrian S, et al. Metabolic
markers distinguish COVID-19 from other intensive care patients and show potential to stratify for
disease risk. medRxiv. 2021:2021.01.13.21249645.

13. Lodge S, Nitschke P, Kimhofer T, Coudert JD, Begum S, Bong S-H, et al. NMR Spectroscopic
Windows on the Systemic Effects of SARS-CoV-2 Infection on Plasma Lipoproteins and Metabolites in
Relation to Circulating Cytokines. Journal of Proteome Research. 2021;20(2):1382-96.

Kimhofer T, Lodge S, Whiley L, Gray N, Loo RL, Lawler NG, et al. Integrative Modeling of
Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan Pathological
Signature of SARS-CoV-2 Infection. Journal of proteome research. 2020;19(11):4442--54, pmid =
32806897.

Aboelela MI, Abd Elmajeed AD, Abd Elmaksoud H, Sayed AA. AStudy on APO B100/APO A1
Ratio as A Predictive Parameter for Assessmentof CAD Risk in Uncontrolled Type 2 Egyptian Diabetic
Patients. The Egyptian Journal of Hospital Medicine. 2014;54(1):62-70.

16. Rendeiro AF, Vorkas CK, Krumsiek J, Singh H, Kapatia S, Cappelli LV, et al. Metabolic and

immune markers for precise monitoring of COVID-19 severity and treatment. medRxiv.2021:2021.09.05.21263141.

17. Luporini RL, Pott-Junior H, Di Medeiros Leal MCB, Castro A, Ferreira AG, Cominetti MR, et al.
Phenylalanine and COVID-19: Tracking disease severity markers. International Immunopharmacology.
2021;101:108313.

730 18. Feingold KR. Lipid and Lipoprotein Levels in Patients with COVID-19 Infections. In: Feingold

KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, et al., editors. Endotext. South
Dartmouth (MA): MDText.com, Inc.

All rights reserved. No reuse allowed without permission.

733 Copyright © 2000-2022, MDText.com, Inc.; 2022. 734 19. Meoni G, Ghini V, Maggi L, Vignoli A, Mazzoni A, Salvati L, et al. Metabolomic/lipidomic 735 profiling of COVID-19 and individual response to tocilizumab. PLOS Pathogens. 2021;17(2):e1009243. 736 20. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute 737 COVID-19 syndrome. Nature Medicine. 2021;27(4):601-15. 738 21. Holmes E, Wist J, Masuda R, Lodge S, Nitschke P, Kimhofer T, et al. Incomplete Systemic 739 Recovery and Metabolic Phenoreversion in Post-Acute-Phase Nonhospitalized COVID-19 Patients: 740 Implications for Assessment of Post-Acute COVID-19 Syndrome. Journal of proteome research. 741 2021;20(6):3315--29, pmid = 34009992. 742 22. Liptak P, Baranovicova E, Rosolanka R, Simekova K, Bobcakova A, Vysehradsky R, et al. 743 Persistence of Metabolomic Changes in Patients during Post-COVID Phase: A Prospective, 744 Observational Study. Metabolites. 2022;12(7):641. Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, et al. GlycA: A 745 23. 746 Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation. Clinical Chemistry. 747 2015;61(5):714-23. 748 24. Fuertes-Martín R, Taverner D, Vallvé J-C, Paredes S, Masana L, Correig Blanchar X, et al. 749 Characterization of 1H NMR Plasma Glycoproteins as a New Strategy To Identify Inflammatory 750 Patterns in Rheumatoid Arthritis. Journal of Proteome Research. 2018;17(11):3730-9. 751 25. Nitschke P, Lodge S, Kimhofer T, Masuda R, Bong S-H, Hall D, et al. J-Edited Diffusional Proton 752 Nuclear Magnetic Resonance Spectroscopic Measurement of Glycoprotein and Supramolecular 753 Phospholipid Biomarkers of Inflammation in Human Serum. Analytical Chemistry. 2022;94(2):1333-754 41. 755 26. Otvos JD, Guyton JR, Connelly MA, Akapame S, Bittner V, Kopecky SL, et al. Relations of GlycA 756 and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of 757 the AIM-HIGH trial. Journal of Clinical Lipidology. 2018;12(2):348-55.e2. 758 Chiesa ST, Charakida M, Georgiopoulos G, Roberts JD, Stafford SJ, Park C, et al. Glycoprotein 27. 759 Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. Journal of the 760 American Heart Association. 2022;11(4):e024380. 761 28. Lodge S, Nitschke P, Kimhofer T, Wist J, Bong S-H, Loo RL, et al. Diffusion and Relaxation 762 Edited Proton NMR Spectroscopy of Plasma Reveals a High-Fidelity Supramolecular Biomarker 763 Signature of SARS-CoV-2 Infection. Analytical Chemistry. 2021;93(8):3976-86. 764 29. Ameta K, Gupta A, Kumar S, Sethi R, Kumar D, Mahdi AA. Essential hypertension: A filtered 765 serum based metabolomics study. Scientific Reports. 2017;7(1):2153. 766 30. Deng Y, Huang C, Su J, Pan C-W, Ke C. Identification of biomarkers for essential hypertension 767 based on metabolomics. Nutrition, Metabolism and Cardiovascular Diseases. 2021;31(2):382-95. 768 31. Nayak P, Panda S, Thatoi PK, Rattan R, Mohapatra S, Mishra PK. Evaluation of Lipid Profile 769 and Apolipoproteins in Essential Hypertensive Patients. J Clin Diagn Res. 2016;10(10):BC01-BC4. 770 32. Würtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, et al. Metabolite 771 Profiling and Cardiovascular Event Risk. Circulation. 2015;131(9):774-85. 772 Del Coco L, Vergara D, De Matteis S, Mensà E, Sabbatinelli J, Prattichizzo F, et al. NMR-Based 33. 773 Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with 774 Type 2 Diabetes Mellitus. Journal of Clinical Medicine. 2019;8(5):720. 775 34. Lim A, Hippchen T, Unger I, Heinze O, Welker A, Kräusslich H-G, et al. An Outpatient 776 Management Strategy Using a Coronataxi Digital Early Warning System Reduces Coronavirus Disease 777 2019 Mortality. Open Forum Infectious Diseases. 2022;9(4). 778 35. Holmes MV, Millwood IY, Kartsonaki C, Hill MR, Bennett DA, Boxall R, et al. Lipids, 779 Lipoproteins, and Metabolites and & #xa0; Risk of Myocardial Infarction and & #xa0; Stroke. Journal of 780 the American College of Cardiology. 2018;71(6):620-32. 781 36. Rader DJ, Hovingh GK. HDL and cardiovascular disease. The Lancet. 2014;384(9943):618-25. 782 37. Superko HR, Pendyala L, Williams PT, Momary KM, King SB, Garrett BC. High-density 783 lipoprotein subclasses and their relationship to cardiovascular disease. Journal of Clinical Lipidology. 784 2012;6(6):496-523.

All rights reserved. No reuse allowed without permission.

78538.Gebhard C, Rhainds D, Tardif J-C. HDL and cardiovascular risk: is cholesterol in particle786subclasses relevant? European Heart Journal. 2014;36(1):10-2.

787 39. Piko P, Kosa Z, Sandor J, Seres I, Paragh G, Adany R. The profile of HDL-C subfractions and
788 their association with cardiovascular risk in the Hungarian general and Roma populations. Scientific
789 Reports. 2022;12(1):10915.

40. De Souza JA, Vindis C, Nègre-Salvayre A, Rye K-A, Couturier M, Therond P, et al. Small, dense
HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. Journal of
Cellular and Molecular Medicine. 2010;14(3):608-20.

Harbaum L, Ghataorhe P, Wharton J, Jiménez B, Howard LSG, Gibbs JSR, et al. Reduced
plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial
hypertension. Thorax. 2019;74(4):380-9.

Florvall G, Basu S, Larsson A. Apolipoprotein A1 Is a Stronger Prognostic Marker Than Are
HDL and LDL Cholesterol for Cardiovascular Disease and Mortality in Elderly Men. The Journals of
Gerontology: Series A. 2006;61(12):1262-6.

Nazir S, Jankowski V, Bender G, Zewinger S, Rye K-A, van der Vorst EPC. Interaction between
high-density lipoproteins and inflammation: Function matters more than concentration! Advanced
Drug Delivery Reviews. 2020;159:94-119.

44. de la Llera Moya M, McGillicuddy FC, Hinkle CC, Byrne M, Joshi MR, Nguyen V, et al.

803 Inflammation modulates human HDL composition and function in vivo. Atherosclerosis.

804 2012;222(2):390-4.

80545.Bindu G H, Rao VS, Kakkar VV. Friend Turns Foe: Transformation of Anti-Inflammatory HDL to806Proinflammatory HDL during Acute-Phase Response. Cholesterol. 2011;2011:274629.

807 46. Rosenson RS, Brewer HB, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, et al. Dysfunctional
808 HDL and atherosclerotic cardiovascular disease. Nature Reviews Cardiology. 2016;13(1):48-60.

Wei X, Zeng W, Su J, Wan H, Yu X, Cao X, et al. Hypolipidemia is associated with the severity
of COVID-19. Journal of Clinical Lipidology. 2020;14(3):297-304.

48. Mahat RK, Rathore V, Singh N, Singh N, Singh SK, Shah RK, et al. Lipid profile as an indicator
of COVID-19 severity: A systematic review and meta-analysis. Clinical Nutrition ESPEN. 2021;45:91101.

49. Páez-Franco JC, Torres-Ruiz J, Sosa-Hernández VA, Cervantes-Díaz R, Romero-Ramírez S,

815 Pérez-Fragoso A, et al. Metabolomics analysis reveals a modified amino acid metabolism that

816 correlates with altered oxygen homeostasis in COVID-19 patients. Scientific Reports.

817 2021;11(1):6350.

818 50. de Oliveira DC, da Silva Lima F, Sartori T, Santos ACA, Rogero MM, Fock RA. Glutamine

metabolism and its effects on immune response: molecular mechanism and gene expression. Nutrire.
2016;41(1):14.

Shi D, Yan R, Lv L, Jiang H, Lu Y, Sheng J, et al. The serum metabolome of COVID-19 patients is
distinctive and predictive. Metabolism. 2021;118:154739.

52. Huang S-S, Lin J-Y, Chen W-S, Liu M-H, Cheng C-W, Cheng M-L, et al. Phenylalanine- and
leucine-defined metabolic types identify high mortality risk in patients with severe infection.
International Journal of Infectious Diseases. 2019;85:143-9.

826 53. Møller N, Meek S, Bigelow M, Andrews J, Nair KS. The kidney is an important site for <i>in

vivo</i> phenylalanine-to-tyrosine conversion in adult humans: A metabolic role of the kidney.
 Proceedings of the National Academy of Sciences. 2000;97(3):1242-6.

54. Tessari P, Vettore M, Millioni R, Puricelli L, Orlando R. Effect of liver cirrhosis on
phenylalanine and tyrosine metabolism. Current Opinion in Clinical Nutrition & Metabolic Care.
2010;13(1):81-6.

832 55. Boirie Y, Albright R, Bigelow M, Nair KS. Impairment of phenylalanine conversion to tyrosine 833 inend-stage renal disease causing tyrosine deficiency. Kidney International. 2004;66(2):591-6.

834 56. Newsholme P, Procopio J, Lima MMR, Pithon-Curi TC, Curi R. Glutamine and glutamate—

their central role in cell metabolism and function. Cell Biochemistry and Function. 2003;21(1):1-9.

All rights reserved. No reuse allowed without permission.

836 57. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al.

Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer
 Cell. 2005;7(1):77-85.

58. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, et al.

Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature. 2013;496(7444):23842.

842 59. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and

843 Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis.
844 Intervirology. 2021;64(1):36-47.

845 60. Viveiros A, Rasmuson J, Vu J, Mulvagh SL, Yip CYY, Norris CM, et al. Sex differences in COVID846 19: candidate pathways, genetics of ACE2, and sex hormones. American Journal of Physiology-Heart
847 and Circulatory Physiology. 2021;320(1):H296-H304.

848 61. Lee CCE, Ali K, Connell D, Mordi IR, George J, Lang EM, et al. COVID-19-Associated 849 Cardiovascular Complications. Diseases. 2021;9(3):47.

850 62. Papandreou C, Moré M, Bellamine A. Trimethylamine N-oxide in relation to cardiometabolic
851 health—cause or effect? Nutrients. 2020;12(5):1330.

852 63. Terruzzi I, Senesi P. Does intestinal dysbiosis contribute to an aberrant inflammatory

response to severe acute respiratory syndrome coronavirus 2 in frail patients? Nutrition. 2020;79-854 80:110996.

Khashkhusha TR, Chan JSK, Harky A. ACE inhibitors and COVID-19: We don't know yet. J Card
Surg. 2020;35(6):1172-3.

857 65. Sharma R, Kumar A, Majeed J, Thakur AK, Aggarwal G. Drugs acting on the renin-

angiotensin–aldosterone system (RAAS) and deaths of COVID-19 patients: a systematic review and
 meta-analysis of observational studies. The Egyptian Heart Journal. 2022;74(1):64.

860 66. Lee T, Cau A, Cheng MP, Levin A, Lee TC, Vinh DC, et al. Angiotensin Receptor Blockers and

Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. CJC Open. 2021;3(7):965-75.